KYTHERA Biopharmaceuticals, Inc., a Calabasas, CA-based biotechnology company focused on the development and commercialization of products in aesthetic medicine, closed a $37.4m Series D financing.
Backers included Versant Ventures, ARCH Venture Partners, Prospect Venture Partners, JAFCO, Partner Funds management (PFM), INVUS Financial Advisors, BBT Capital Management/Apothecary Capital, Altitude Life Science Ventures, as well as new investors Foley Ventures and Latham and Watkins.
This funding brings the total amount raised by KYTHERA to date to more than $108M in four rounds.
The company intends to use the capital to conduct US Phase III trials for its lead product, ATX-101, an injectable drug that is under investigation for the reduction of submental (under the chin) fat.
The trials are expected to start late in 2011 or early 2012.
Led by President and CEO Keith Leonard, KYTHERA also has active research programs with focused interest in hair and fat biology, pigmentation modulation and facial contouring.